October 28, 2026
2 min read
Key takeaways:
Adults receiving retatrutide 9 mg or 12 mg had a 2.2 percentage point drop in HbA1c compared with 1.8 percentage points with Ozempic 2 mg.
Weight loss was higher in both retatrutide groups compared with Ozempic.
Once-weekly retatrutide induced greater declines in HbA1c and body weight than Ozempic 2 mg for adults with type 2 diabetes, according to topline results from the phase 3 open-label TRASCEND-T2D-2 trial.
As Healio previously reported, the TRANSCEND-T2D-1 trial found that retatrutide (Eli Lilly), a subcutaneous GLP-1, GIP and glucagon triple receptor agonist, reduced HbA1c and body weight more than placebo for adults with type 2 diabetes. In TRANSCEND-T2D-2, 1,298 adults with type 2 diabetes who were unable to achieve glycemic control with metformin with or without an SGLT2 inhibitor were randomly assigned 2:2:1 to receive retatrutide 9 mg, retatrutide 12 mg, or Ozempic 2 mg (semaglutide, Novo Nordisk) for 80 weeks. All participants had an HbA1c of 7% to 10.5% at baseline. The primary outcome was noninferiority of retatrutide 12 mg compared with Ozempic for HbA1c reduction at 80 weeks.
Retatrutide 9 mg and 12 mg conferred greater decreases in both HbA1c and body weight than Ozempic 2 mg for adults with type 2 diabetes. Image: Adobe Stock
According to the efficacy estimand, both the retatrutide 9 mg and 12 mg groups had 2.2 percentage point declines in HbA1c at 80 weeks, which were greater than the 1.8 percentage point drop observed with Ozempic 2 mg (P < .001 for both). Adults receiving retatrutide 12 mg had a 20.9% decrease in body weight, and those receiving the 9 mg dose had a 19.5% decline in weight compared with a 9.4% weight loss with Ozempic at 80 weeks (P < .001 for both).
According to the press release, both retatrutide groups also had greater improvements in non-HDL cholesterol, triglycerides and systolic blood pressure than the Ozempic group.
The most common adverse events reported with retatrutide were diarrhea, nausea, constipation, vomiting and dyspepsia. Most adverse events were mild to moderate in severity and resolved during treatment. The proportion of adults who stopped treatment due to adverse events was 4.8% with retatrutide 9 mg and 7.9% with the 12 mg dose compared with 2.7% with Ozempic.
“Head-to-head trials show patients and physicians how a potential new medicine compares with treatments that are available and reimbursed today,” Kenneth Custer, PhD, executive vice president and president of Lilly Cardiometabolic Health, said in a press release. “In TRANSCEND-T2D-2, the first phase 3 trial comparing retatrutide with another incretin medicine, retatrutide delivered greater HbA1c reduction and more than double the weight loss of the highest approved dose of Ozempic for type 2 diabetes. Based on these results and those from across our phase 3 program, we believe retatrutide, if approved, could shift the treatment paradigm for people living with type 2 diabetes, obesity and related cardiometabolic conditions.”
Full results from TRANSCEND-T2D-2 will be presented at a future medical conference and published in a peer-reviewed journal, according to the release.